Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Vaxcyte, Inc. Director's Dealing 2024

Mar 5, 2024

31100_dirs_2024-03-04_1a3e2d83-4c22-4615-b545-7d35a198285b.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Vaxcyte, Inc. (PCVX)
CIK: 0001649094
Period of Report: 2024-02-29

Reporting Person: Eydelman Mikhail (N/A)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2024-02-29 Common Stock A 10500 Acquired 31210 Direct
2024-03-01 Common Stock M 1667 $21.41 Acquired 32877 Direct
2024-03-01 Common Stock S 519 $73.025 Disposed 32358 Direct
2024-03-01 Common Stock S 703 $73.59 Disposed 31655 Direct
2024-03-01 Common Stock S 445 $74.771 Disposed 31210 Direct
2024-03-02 Common Stock F 613 $71.55 Disposed 30597 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2024-02-29 Stock Option (right to buy) $73.82 A 50000 Acquired 2034-02-28 Common Stock (50000) Direct
2024-03-01 Stock Option (right to buy) $21.41 M 1667 Disposed 2032-05-08 Common Stock (1667) Direct

Footnotes

F1: Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs vest as to 25% of the shares subject to the award on August 31, 2024 and 12.5% of the shares every six months thereafter, subject to Reporting Person's continuous service with the Issuer through each such date.

F2: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 29, 2023.

F3: The price reported is a weighted-average price. The shares were sold at prices ranging from $72.39 to $73.325. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

F4: The price reported is a weighted-average price. The shares were sold at prices ranging from $73.42 to $73.74. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

F5: The price reported is a weighted-average price. The shares were sold at prices ranging from $74.55 to $74.95. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

F6: Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of restricted stock units.

F7: 1/48 of shares subject to the option vest on March 31, 2024, and 1/48 of the shares vest monthly thereafter, subject to Reporting Person's continuous service with the Issuer through each such date.

F8: 1/4 of the shares subject to the option shall vest on April 1, 2023, and 1/48 of the shares shall vest monthly thereafter, subject to Reporting Person's continuous service to the Company through each such date.